Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD
Sign Up to like & getrecommendations! Published in 2022 at "ERJ Open Research"
DOI: 10.1183/23120541.00207-2022
Abstract: Background Anti-eosinophilic therapy with interleukin-5/interleukin-5-receptor antibodies represents an established treatment for patients with severe eosinophilic asthma (SEA) but did not show clinical efficacy in patients with COPD. The objective of the present study was to… read more here.
Keywords: sea copd; receptor antibodies; patients sea; interleukin receptor ... See more keywords